Literature DB >> 21329799

Using temporal genetic switches to synchronize the unfolded protein response in cell populations in vivo.

Alexander Gow1.   

Abstract

In recent years, recognition of the importance of protein aggregation in human diseases has increasingly come to the fore and it is clear that many degenerative disorders involve activation of a metabolic signaling cascade known as the unfolded protein response (UPR). The UPR encompasses conserved mechanisms in cells to monitor and react to changes in metabolic flux through the secretory pathway. Such changes reflect an imbalance in cell homeostasis and the UPR integrates several signaling cascades to restore homeostasis. As such, the UPR is simply interpreted as a protection mechanism for cells as they perform their normal functions. A number of groups have suggested that the UPR also can eliminate cells in which homeostasis is lost, for example, during disease. This notion has kindled the rather paradoxical concept that inhibiting the UPR will ameliorate degenerative disease. However, several in vivo studies in the nervous system indicate that curtailing UPR function either exacerbates disease or may reduce severity through unexpected or unidentified pathways. Perhaps the notion that the UPR protects cells or eliminates them stems from widespread use of suboptimal paradigms to characterize the UPR; thus, too little is currently known about this homeostatic pathway. Herein, I describe the development of genetic switch technology (GST) to generate a novel model for studying UPR diseases. The model is geared toward obtaining high resolution in vivo detail for oligodendrocytes of the central nervous system, but it can be adapted to study other cell types and other UPR diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21329799      PMCID: PMC3070952          DOI: 10.1016/B978-0-12-385928-0.00009-2

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  60 in total

Review 1.  The unfolded protein response in protein aggregating diseases.

Authors:  Alexander Gow; Ramaswamy Sharma
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  That which does not kill me makes me stronger: adapting to chronic ER stress.

Authors:  D Thomas Rutkowski; Randal J Kaufman
Journal:  Trends Biochem Sci       Date:  2007-10       Impact factor: 13.807

3.  The rumpshaker mutation in spastic paraplegia.

Authors:  H Kobayashi; E P Hoffman; H G Marks
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

4.  Jimpy(msd) mouse mutation and connatal Pelizaeus-Merzbacher disease.

Authors:  T Yamamoto; E Nanba; H Zhang; M Sasaki; H Komaki; K Takeshita
Journal:  Am J Med Genet       Date:  1998-02-03

5.  Conservative amino acid substitution in the myelin proteolipid protein of jimpymsd mice.

Authors:  S Gencic; L D Hudson
Journal:  J Neurosci       Date:  1990-01       Impact factor: 6.167

6.  The evolution of lipophilin genes from invertebrates to tetrapods: DM-20 cannot replace proteolipid protein in CNS myelin.

Authors:  B Stecca; C M Southwood; A Gragerov; K A Kelley; V L Friedrich; A Gow
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

7.  The unfolded protein response modulates disease severity in Pelizaeus-Merzbacher disease.

Authors:  Cherie M Southwood; James Garbern; Wei Jiang; Alexander Gow
Journal:  Neuron       Date:  2002-11-14       Impact factor: 17.173

8.  Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease.

Authors:  Stephanie Hurst; James Garbern; Angela Trepanier; Alexander Gow
Journal:  Genet Med       Date:  2006-06       Impact factor: 8.822

9.  Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease.

Authors:  A Gow; C M Southwood; R A Lazzarini
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

10.  Efficient mouse transgenesis using Gateway-compatible ROSA26 locus targeting vectors and F1 hybrid ES cells.

Authors:  Omar Nyabi; Michael Naessens; Katharina Haigh; Agnieszka Gembarska; Steven Goossens; Marion Maetens; Sarah De Clercq; Benjamin Drogat; Lieven Haenebalcke; Sonia Bartunkova; Ilse De Vos; Bram De Craene; Mansour Karimi; Geert Berx; Andras Nagy; Pierre Hilson; Jean-Christophe Marine; Jody J Haigh
Journal:  Nucleic Acids Res       Date:  2009-03-11       Impact factor: 16.971

View more
  2 in total

Review 1.  Finding degrees of separation: experimental approaches for astroglial and oligodendroglial cell isolation and genetic targeting.

Authors:  Li-Jin Chew; Cynthia A DeBoy; Vladimir V Senatorov
Journal:  J Neurosci Methods       Date:  2014-08-26       Impact factor: 2.390

2.  Corticohippocampal Dysfunction In The OBiden Mouse Model Of Primary Oligodendrogliopathy.

Authors:  Daniel Z Radecki; Elizabeth L Johnson; Ashley K Brown; Nicholas T Meshkin; Shane A Perrine; Alexander Gow
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.